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Abstract
Motivation
The literature on complex diseases is abundant but not always quantitative. This is particu-
larly so for Inflammatory Bowel Disease (IBD), where many molecular pathways are qualita-
tively well described but this information cannot be used in traditional quantitative
mathematical models employed in drug development. We propose the elaboration and vali-
dation of a logic network for IBD able to capture the information available in the literature
that will facilitate the identification/validation of therapeutic targets.
Results
In this article, we propose a logic model for Inflammatory Bowel Disease (IBD) which con-
sists of 43 nodes and 298 qualitative interactions. The model presented is able to describe
the pathogenic mechanisms of the disorder and qualitatively describes the characteristic
chronic inflammation. A perturbation analysis performed on the IBD network indicates that
the model is robust. Also, as described in clinical trials, a simulation of anti-TNFα, anti-IL2
and Granulocyte and Monocyte Apheresis showed a decrease in the Metalloproteinases
node (MMPs), which means a decrease in tissue damage. In contrast, as clinical trials have
demonstrated, a simulation of anti-IL17 and anti-IFNγ or IL10 overexpression therapy did
not show any major change in MMPs expression, as corresponds to a failed therapy. The
model proved to be a promising in silico tool for the evaluation of potential therapeutic tar-
gets, the identification of new IBD biomarkers, the integration of IBD polymorphisms to antic-
ipate responders and non-responders and can be reduced and transformed in quantitative
model/s.
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Introduction
Inflammatory bowel disease (IBD) is a complex gastrointestinal tract disorder characterized by
a functional impairment of the gut wall affecting patients´ quality of life [1,2]. IBD includes
ulcerative colitis (UC) and Crohn’s disease (CD). The natural course of IBD is highly variable
[3–6] and its etiology is still unknown. The incidence of IBD has dramatically increased world-
wide over the past 50 years [7], reaching levels of 24.3 per 100,000 person-years in UC and 20.2
per 100,000 person-years in CD in the developed countries [8].
There is current evidence that Interleukin 6 (IL6), Tumour necrosis factor-alpha (TNFα),
Interferon Gamma (IFNƔ), Interleukin 1 beta (IL1ß), Interleukin 22 (IL22), Interleukin 17
(IL17) and Natural Killer cells (NK), among other signalling pathways, play relevant roles in
the pathogenesis of IBD, which is a reflection of the complexity of that physiological system
[9–12]. That complexity indicates that a universal treatment for IBD may not be feasible for
the vast majority of patients [13,14]. In fact, current biological approved treatments are only
palliative with a high percentage of non-responders. For example, around 50% of IBD patients
treated with the current standard of care, Infliximab (an anti-TNFα) or Vedolizumab (an anti-
α4β7 integrin) do not respond satisfactorily to therapy [15,16]. One characteristic of the cur-
rent IBD biological treatments is that approved therapies target just one signalling pathway,
which might explain the high rate of non-responders and the long-term inefficiency of most
treatments [15,17]. In addition, there is evidence to suggest that optimal treatment for IBD
should involve a combination of different drugs [18,19]. Therefore, there is a need, especially
for complex alterations such as immune-mediated diseases, to change the paradigm of drug
development, considering the main aspects (targets, cross-talking between pathways, therapy
combination) from an integrative and computational perspective.
Given the aforementioned biological complexity of immune-mediated diseases and the fact
that current longitudinal data associated with the most relevant elements of the system are
scarce, a full parameterization of IBD related systems based on a differential equation model
does not yet seem feasible. However, some attempts have been made to describe quantitatively
the IBD systems. For example, Wendelsdorf et al., [20] built a quantitative model based on
ordinary differential equations. However, some key disease elements, such as cytokines and T
cells, were incorporated non-specifically (i.e., all types of cytokine were grouped under the
generic element active cytokines) in the model structure, limiting its use to explore potential
therapeutic targets. More recently, Dwivendi et al., [21], based on the results of a clinical trial
with the anti–IL6R antibody, Tocilizumab, have developed a multiscale systems model in
Crohn’s disease, limited to the IL6–mediated immune regulation pathway.
Network analysis represents a promising alternative in such data limited circumstances
[22–24]. As many molecular pathways in IBD are qualitatively well described, interaction net-
works may be a suitable approach for characterizing IBD. These networks are simplified repre-
sentations of biological systems in which the components of the system such as genes, proteins
or cells are represented by nodes and the interactions between them by edges [25]. Boolean
network models, originally introduced by Kauffman [26,27], represent the simplest discrete
dynamic models. These models only assume two discrete states for the nodes of a network,
ON or OFF, corresponding to the logic values 1 (active) or 0 (not active, but not necessarily
absent) [28]. A well-designed logic model could generate predictive outcomes given a set of
initial conditions. Qualitative, logical frameworks have emerged as relevant approaches with
different applications, as demonstrated by a growing number of published models [29]. Com-
plementing these applications, several groups have provided various methods and tools to sup-
port the definition and analysis of logical models, as it can be seen by the recent achievements
of the Consortium for Logical Models and Tools (CoLoMoTo) in logical modelling [30].
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There are already several tools for Boolean modeling of regulatory networks in which it is pos-
sible to define direct activation-inhibition relationships between the components of the net-
work, such as BoolNet R [31] or GINsim [32]. More recently, the R package SPIDDOR
(Systems Pharmacology for effIcient Drug Development On R) among others, has imple-
mented new types of regulatory interactions and perturbations within the system, such as posi-
tive and negative modulators and the polymorphism-like alterations, which lead to richer
dynamics between the nodes [28].
In the specific case of IBD, there have been initial attempts to develop network models. The
multi-state modeling tool published by Mei et al., [33,34] can be considered a proof of concept
in the application of these types of networks in mucosal immune responses. However, the
number of elements that this model considers and integrates is limited for IBD characteriza-
tion, since only six different cytokine types are included in the inter-cellular scale.
The objective of the current manuscript is to present a Boolean based network model incor-
porating the main cellular and protein components known to play a key role in IBD develop-
ment and progression. The model has been built on well-established experimental knowledge,
mostly of human origin, and only including animal data when no other source of information
was available. Our aim has been to build a model structure facilitating key aspects in the treat-
ment of immune mediated disease, such as the selection of the most promising combination
therapies and the study of the impact of polymorphisms on pathway regulation, thus allowing
patient stratification and personalized medicine.
This study provides the scientific community with a (i) computational IBD model imple-
mented in SPIDDOR R package [28], which allows translation of Boolean models (excluding
models enclosing temporal operators) to a standard Markup language in Systems Biology for
qualitative models (SBML qual [35]) which promotes model interoperability, and (ii) a reposi-
tory with the main and updated information known of the immune system and IBD, which
shows model transparency and allows model reusability. The proposed IBD model can be eas-
ily expanded in size and complexity to incorporate new knowledge, or other type of informa-
tion such as proteomic data. The model presented hereafter is general enough to serve as a
skeleton for other relevant immune diseases such as Rheumatoid Arthritis, Psoriasis or Multi-
ple Sclerosis.
The manuscript is organized as follows: In the next section, Results regarding the structure
of the model can be graphically visualized, and the ability of the model to recreate certain alter-
ations that have been reported in IBD is demonstrated, as well as the model’s capability to
reproduce the results from recent clinical trials performed in IBD patients from a high-level
perspective. Applications of the model, including its advantages and limitations are then dis-
cussed together with ideas for future research. Finally, the Methods section provides a detailed
technical description (with the aid of supplementary material) of the network and a descrip-
tion of how simulations, collection, and representation of results have been performed.
Results
Graphical representation, repository, and Boolean functions
The graphical representation of the IBD network is shown in Fig 1. It consists of 43 nodes and
298 qualitative interactions located in three different physiological areas corresponding to (i)
the lymph node, (ii) the blood and lymph circulatory system that irrigates the intestinal epithe-
lial cells and (iii) the gut lumen.
Definition of all nodes and the full documented regulatory interactions conforming the
model structure can be found in supporting information S1 Table and S2 Table, respectively.
The S2 Table is fundamental to understand the rationale for the selection and implementation
A systems pharmacology model for IBD
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of the Boolean functions (BF). It was organized to provide a comprehensive summary of the
301 manuscripts (published over the last three decades) used to build the model, highlighting
for example whether (i) a specific pathway was reported to be altered in IBD, or (ii) informa-
tion was supported by human (more than the 80% of the network structure) or animal data.
The Boolean operators used to define the network model of IBD were: the NOT operator
which is noted as “!”, the AND operator which is noted as “&” and the OR operator which is
noted as “|”. Recent and innovative modulators and threshold operators previously described
by Irurzun-Arana et al., 2017 [28] were also part of the arsenal of Boolean elements used in the
model proposed (see S1 File for a detailed description of those additional Boolean elements).
Regarding the input selection, as it is assumed that IBD is caused by intestinal dysbiosis, an
environment of different bacteria was recreated selecting three different antigens which are
components of most Bacterial Gram positive and Gram negative. Therefore, during the devel-
opment of the proposed model the following assumptions were made: First, there is a chronic
exposure to bacterial antigens: Peptidoglycan (PGN), Lipopolysaccharide (LPS) and Muramyl
dipeptide (MDP). PGN is a component of the cell wall of all bacteria, but in particular of
gram-positive bacteria, LPS is a component of the outer membrane of Gram-negative bacteria
Fig 1. Graphical representation of IBD model. Nodes represent cells, proteins, bacterial antigens, receptors or ligands. Bacterial antigens trigger the IBD immune
response through activation of different pattern recognition receptors (TLR2, TLR4 and NOD2) starting the innate and adaptive immune response. Reprinted from [36]
under a CC BY license, with permission from the organizers of the 2016 International Conference on Systems Biology, original copyright 2016.
https://doi.org/10.1371/journal.pone.0192949.g001
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[37], and MDP is a constituent of both Gram-positive and Gram-negative bacteria [38]. All
three elicit strong immune responses and seem to play a critical role in the development and
pathophysiology of IBD, as it has been hypothesized that the onset or relapse of IBD is trig-
gered by an imbalance in self-microbiota composition than cannot be controlled by immune
system [39]. Table 1 lists the initial conditions expressed by the corresponding BF, and shows
that the nodes representing antigens are chronically expressed unless the natural antimicrobial
peptides perforin (PERFOR), granzyme B (GRANZB) or defensins (DEF) become active.
Second, there is an impairment in antigen elimination in IBD patients [1,40,41], simulated
with the threshold operator Ag_elim = 6. The threshold operator means that PERFOR,
GRANZB, or DEF inhibit antigen activation when any of these three nodes have been activated
for at least 6 consecutive iterations (see Table 1).
Third, the final readout of the network model is the average expression of the output node,
Metalloproteinases (MMPs). There is solid evidence that this group of proteins is directly asso-
ciated with intestinal fibrosis and tissue damage in IBD [42–46] supporting their use as a rele-
vant biomarker in clinical practice as proposed by O’Sullivan et al. [47]. As it can be seen in
Table 2, the nodes that directly activate MMPs are the nodes that have relevant roles in the
pathogenesis of IBD [9–12,42–44,46,48].
Table 2 contains the full set of BF that modulates the signal initialized by the antigens
through the activation of different pattern recognition receptors (TLR2, TLR4 and NOD2
nodes) and the impact on the output node (MMPs) as the recipient of the antigen signal inter-
nal modulation. The nodes TNFα or IFNγ have the most complex pathways as can be seen in
the corresponding Boolean equations (Table 2).
With the aim of making the network model more accessible to the community it has been
uploaded to “The Cell Collective” [49,50] platform (https://www.cellcollective.org/#cb963d7f-
75cb-4b2e-8987-0c7592a9c21d). In addition, the supporting information document S2 File
provides the network model in text format ready for simulation in the R-based freely available
package SPIDDOR [28] and an html tutorial as a guide to reproduce the results (S3 File).
Perturbation analysis and clustering: Network robustness
The results of the network perturbation analysis are presented in Fig 2. The heatmap shows
the impact of a single blockage of each node in every network node. The results indicate that
most node blockages did not trigger considerable changes, suggesting that the IBD network is
robust [51]. Some perturbations led to a higher activation of the nodes, while down regulations
were more common. The heatmap was combined with a hierarchical clustering grouping
together the nodes that caused similar alterations. Knockout of the NFkß node appeared to be
the most relevant alteration as it caused a reduction in expression of many of the nodes that
were reported to be overexpressed in IBD patients. The knockout of the Th0 node (represent-
ing activated CD4+ T cells) also elicited a reduction in MMPs. The positive effects of the NFkß
and Th0 node blockades on MMPs decreased expression, resembled some of the known mech-
anisms of action of glucocorticoids, inhibitors of T cell activation and proinflammatory
Table 1. Boolean functions (BF) of the IBD model to simulate the initial conditions.
INITIAL CONDITIONS: CHRONIC EXPOSURE
PGN ¼ ! ð
TAG  elim¼6
i¼1 PERFORt  i j
TAG  elim¼6
i¼1 GRANZBt  i j
TAG  elim¼6
i¼1 DEFt  iÞ
MDP ¼ ! ð
TAG  elim¼6
i¼1 PERFORt  i j
TAG  elim¼6
i¼1 GRANZBt  i j
TAG  elim¼6
i¼1 DEFt  iÞ
LPS ¼ ! ð
TAG  elim¼6
i¼1 PERFOR
t  i j
TAG  elim¼6
i¼1 GRANZB
t  i j
TAG  elim¼6
i¼1 DEF
t  iÞ
https://doi.org/10.1371/journal.pone.0192949.t001
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Table 2. Boolean functions (BF) of the IBD model for the internal and the output nodes.
INTERNAL NODES
TLR2 = PGN
TLR4 = LPS
NOD2 = MDP
NFkB = TLR2 | NOD2 | TLR4
IL6 = (MACR & PGN) | (DC& (LPS | PGN)) | (Th17 & IL23) | (NFkB &! (IL4 | IL10))
TNFa ¼ ððNFkB&LPSÞ j ðMACR&ðIL2 j ðIFNg&LPSÞ j PGNÞÞ j ðNK&ðMDP j PGN j LPSÞ&ððIL2 j
IL12Þ&ðIL2 jIL15ÞÞ j ðFIBROBLAST&IFNgÞ j ððCD4 NKG2D j CD8 NKG2D j NK NKG2DÞ&ðIEC MICA B j
IEC ULPB1 6ÞÞÞ&! ð
Tdownregcyt¼4
i¼1 IL10
t  i&ð
Tdownregcyt¼4
i¼1 TLR2
t  i j
Tdownregcyt¼4
i¼1 TLR4
t  iÞ&TNFaÞ
TGFb = (Treg | MACR)
Th0 ¼
TTHR Th0¼3
i¼1 LPS
t  i j
TTHR Th0¼3
i¼1 MDP
t  i j
TTHR Th0¼3
i¼1 PGN
t  i
Th0_M = (Th0 & (IL23 | IL12)) | Th0_M
IL18 = ((MACR | DC) & LPS) & NFkB
IL1b ¼ ððMACR j DCÞ&LPS&NFkBÞ&! ðIL1b&
Sdownreg cyt¼4
i¼1 IL10
t  iÞ
IFNg ¼ ððNK&ðPGNjLPSjMDPj&ðIL23jðIL12&ðIL2jIL15 jIL18ÞÞÞÞ j ðTh0 M&ðLPS jMDP j PGNÞ
&ðIL12 j IL23ÞÞ j Th1 j ððCD8 NKG2D j NK NKG2DÞ&ðIEC MICA B j IEC ULPB1 6ÞÞ j ðTh17&ðPGN j LPSj
MDPÞÞ j ððMACR j Th0Þ&IL18&IL12ÞÞ&! ððIFNg&ð
Tdownreg cyt¼4
i¼1 TGFb
t  i j
Tdownregcyt¼4
i¼1 IL10
t  i j Th2Þ
IL23 = (MACR & IL1b) | DC
IL22 ¼ Th17jðNK&ððIL18&IL12Þ j IL23ÞÞjCD4 NKG2DjðððIL22&Th0&IL21Þ&!ð
Tupreg cyt¼3
i¼1 IL22
t  i&
Tupreg cyt¼3
i¼1 Th0
t  i&
Tupreg cyt¼3
i¼1 IL21
t  iÞÞ&! TGFbÞ
IL21 = Th17 | ((Th0 & IL6) &! (IL4 | IFNg | TGFb))
IL17 ¼ ðTh17 j ðTh17 M&ðLPS jMDP j PGNÞÞ j ðCD4 NKG2D&ðIEC MICA B j IEC ULPB1 6ÞÞÞ&!
ðð
Tdownreg cyt¼4
i¼1 TGFb
t  i j
Tdownreg cyt¼4
i¼1 IL13
t  iÞ&IL17Þ
IL10 = Treg|(Th2 &! IL23)|((TLR2 & NFkB) &! (MACR & IFNg)) | ((MACR & LPS) &! IL4) | (DC & LPS)
Th17 ¼ ððTh0&ðIL1b j IL23 j IL6ÞÞ j ððTh17&IL23Þ&!ð
Tupreg cell¼2
i¼1 Th17
t  i&
Tupreg cell¼2
i¼1 Il23
t  iÞÞÞ&!
ðð
Sdownreg cell¼2
i¼1 TGFb
t  i j
Sdownreg cell¼2
i¼1 IL12
t  i j
Sdownreg cell¼2
i¼1 IL4
t  ij
Sdownreg cell¼2
i¼1 IFNg
t  i j
Sdownreg cell¼2
i¼1 Treg
t  iÞ&Th17Þ
Th17_M = ((Th0_M & (PGN | MDP | LPS)) & ((IL1b & IL6) | IL23 | IL2)) | Th17_M
Th1 ¼ ðTh0&ððIL12 j IFNg j IL18Þ j ðDC&IL12&IL23&LPSÞÞÞ&! ððð
Sdownreg cell¼2
i¼1 IL17
t  i&
Sdownreg cell¼2
i¼1 IL12
t  iÞ j ð
Sdownreg cell¼2
i¼1 Treg t  i j
Sdownreg cell¼2
i¼1 Th2
t  i j
Sdownreg cell¼2
i¼1 TGFbt  i j
Sdownreg cell¼2
i¼1 IL10
t  i j
Sdownreg cell¼2
i¼1 IL4
t  iÞÞ&Th1Þ
Th2 ¼ ðTh0&ðIL10 jððIL18&IL4Þ&!IL12ÞÞj ððTh2&IL4Þ&!ð
Tupreg cell¼2
i¼1 Th2
t  i&
Tupreg cell¼2
i¼1 IL4
t  iÞÞÞ&!
ðð
Sdownreg cell¼2
i¼1 Treg
t  ij
Sdownreg cell¼2
i¼1 IFNg
t  i j
Sdownreg cell¼2
i¼1 TGFb
t  i
Þ&Th2Þ
IL4 = Th2
IL15 = (FIBROBLAST & (MDP | LPS | PGN)) | (MACR & (LPS | IFNg))
IL12 ¼ ððððMACR j DCÞ&ðLPS jPGNÞ&IFNgÞ&!ðIL12&
Sdownreg cyt¼4
i¼1 TNFat  iÞÞ j ðDC&IL1bÞ j
ðIL12&ðIL13 j IL4ÞÞÞ&!ðð
Sdownreg cyt¼4
i¼1 TGFb
t  i j
Sdownreg cyt¼4
i¼1 IL10
t  iÞ&IL12Þ
IL13 = Th2
Treg ¼ ð
TTHR Th0 Treg¼3
i¼1 Th0
t  i&ðTGFb j TLR2ÞÞ&! ðð
Sdownreg cell¼2
i¼1 IL6
t  i j
Sdownreg cell¼2
i¼1 IL21
t  i j
Sdownreg cell¼2
i¼1 IL23
t  i j
Sdownreg cell¼2
i¼1 Th17
t  i j
Sdownreg cell¼2
i¼1 IL22
t  i j
Sdownreg cell¼2
i¼1 TNFa
t  iÞ&Treg Þ
NK ¼ ðIL15 jIL2 j IL12 jIL23j ðIL18&IL10ÞÞ&! ð
Sdownregcell¼2
i¼1 Treg
t  i&NKÞ
DEF ¼ IL22 j IL17 j
TTHR NOD2 DEF¼3
i¼1 NOD2
t  i
IL2 = Th0 | (Th0_M & (MDP | LPS | PGN)) | DC
MACR ¼ ðNFkB j ððMACR&ðIFNg jIL15ÞÞ&! ð
Tupreg cell¼2
i¼1 NFkB
t  i&ð
Tupreg cell¼2
i¼1 IFNg
t  i j
Tupreg cell¼2
i¼1 IL15
t  iÞÞÞÞ&! ð
Sdownreg cell¼2
i¼1 IL10
t  i&MACRÞ
DC ¼ NFkB&! ð
Sdownreg cell¼2
i¼1 IL10
t  i&DCÞ
IEC MICA B ¼ ððLPS jMDP j PGNÞ j ðIEC MICA B&TNFaÞ&! ð
Tupreg rec¼2
i¼1 IEC MICA B
t  i&
Tupreg rec¼2
i¼1 TNFa
t  iÞÞ&! TGFb
IEC_ULPB1_6 = CD8_NKG2D & (LPS|MDP|PGN)
CD8 NKG2D ¼ ðLPS j PGN jMDPÞ&!ðð
TTHR LIGANDS NKG2D¼3
i¼1 IEC MICA B
t  i j
TTHR LIGANDS NKG2D¼3
i¼1 IEC ULPB 1 6
t  i
j ð
Sdownreg cell¼2
i¼1 IL21
t  i&
Sdownreg cell¼2
i¼1 IL2
t  iÞÞ&CD8 NKG2DÞ
NK NKG2D ¼ ðLPSjPGNjMDPÞ&! ð
Sdownreg cell¼2
i¼1 TGFb
t  i j
TTHR LIGANDS NKG2D¼3
i¼1 IEC MICA B
t  i j
TTHR LIGANDS NKG2D¼3
i¼1 IEC ULPB 1 6
t  i jð
Sdownreg cell¼2
i¼1 IL21
t  i&
Sdownreg cell¼2
i¼1 IL12
t  iÞÞ&NK NKG2DÞ
CD4 NKG2D ¼ ðLPS j PGN jMDP j ðCD4 NKG2D&ðIL15 j TNFaÞÞ&! ð
Tupreg rec¼2
i¼1 CD4 NKG2D
t  i
&ð
Tupreg rec¼2
i¼1 IL15
t  i j
Tupreg rec¼2
i¼1 TNFa
t  iÞÞÞ&! ðð
Sdownreg cell¼2
i¼1 IL10
t  i j
TTHR LIGANDS NKG2D¼3
i¼1 IEC MICA B
t  i j
TTHR LIGANDS NKG2D¼3
i¼1 IEC ULPB 1 6
t  iÞ&CD4 NKG2DÞÞ
FIBROBLAST ¼ ððMACR&ðIL4 j IL13 j TGFbÞÞjIL2Þ&!ðð
Sdownreg cell¼2
i¼1 IFNgt  i j
Sdownreg cell¼2
i¼1 IL12
t  iÞ
&FIBROBLASTÞ
PERFOR = NK | NK_NKG2D
(Continued)
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cytokines, as well as potent suppressors of the effector function of monocyte-macrophage and
fibroblastic activity, interfering with the NFκB inflammatory signal [52–54].
Network accuracy and validation
Experimental and clinical information. Simulations of chronic infection in IBD individ-
uals show that the model reproduced satisfactorily experimental and clinical information
(summarized in Table 3 and supporting information S3 Table). Fig 3 shows the results of the
simulation for each network node after reaching the attractor state for virtual healthy and IBD
subjects. In total, 31 upregulations in experimental studies were replicated with our simula-
tions. Similarly, the 9 nodes reported as altered appeared upregulated in the simulations, and
finally, the three nodes whose profiles were not known also proved to be upregulated.
Clinical trials. In our simulations, three drugs that have failed to prove clinical efficacy in
clinical trials (anti-IL17, anti-IFNγ and rhuIL-10) also exhibited no benefit in the simulated
surrogate for the disease score (Fig 4). Simulations with anti-TNFα, a biologic therapy
approved for IBD, showed a decrease in the disease score. Simulations with anti-IL12-IL23, a
recently approved therapy for IBD, showed a slight decrease in MMPs and anti-IL2 therapy
simulation showed a decrease similar to anti-TNFα. In addition, the new promising therapy
(GMA), equivalent to an anti-MACR in our model showed a decrease in MMPs similar to that
for anti-TNFα.
Discussion
In the current study, we present a Systems Pharmacology (SP) network model for IBD based
on the main cells and proteins involved in the disease. Our analysis appears timely, as IBD has
recently been attracting increasing attention [55–59]. We attempted to meet one of the major
challenges in inflammatory bowel disease (IBD) which is the integration of IBD-related infor-
mation to construct a predictive model. We are not the only ones following this line of
research, as Lauren A Peters et al. have very recently performed a key driver analysis to identify
the genes predicted to modulate network regulatory states associated with IBD [55]. Both anal-
yses could be integrated in the future and inform our post-transcriptomic network with the
key driver genes identified by Lauren A Peters et al. [55].
In comparison with the previous quantitative approaches for IBD [20,21,33,34], our model
identified Naive CD4+ T Cells, Macrophages and Fibroblasts cells as relevant in IBD. Also, in
addition to the six interleukins (TGFß, IL6, IL17, IL10, IL12 and IFNγ) considered by Mei
et al. [33,34] our network involves 10 interleukins more which could represent possible IBD
biomarkers [60]. The procedure to evaluate the potential role of the different components on
the disease as plausible biomarkers, would be equal to the one described in section 4.5 (pertur-
bation analysis and clustering), focussing on the changes in the output node.
In the validation of network models, robustness and practical applicability represent critical
aspects. The fact that the information gathered from the literature was obtained under very
Table 2. (Continued)
GRANZB= CD8_NKG2D | NK | NK_NKG2D | (DC&! (LPS | PGN))
OUTPUT NODE
MMPs = (MACR & TNFa) | (FIBROBLAST & (IL21 | IL17 | IL1b | TNFa))
Bold text within Boolean equations indicates that the information belongs to animal data
https://doi.org/10.1371/journal.pone.0192949.t002
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different experimental designs/conditions/methodologies, represents a challenge with respect
to validation. This led us to propose and adopt a novel strategy consisting of the comparison of
the results of model-based virtual pathway simulations with those reported in the literature for
IBD patients. Using this approach, we obtained a qualitative reproduction of IBD in which all
the network elements that have been reported as upregulated in IBD patients appeared upre-
gulated in our simulation results. The perturbation analysis of the network was performed by a
single blockage in each node to analyse how that type of alteration propagates through the
entire network reflecting the case of single polymorphisms, which represents the simplest case
of IBD disease. Despite of the simplicity of this analysis, the results obtained from the model
accuracy and validation procedures are encouraging. Results from the perturbation analysis
indicate that the proposed network model is robust, as alteration in most nodes did not trigger
considerable changes in the network [61].
Once validated and checked for robustness, the network was challenged to qualitatively
reproduce the readouts of five different therapies reported in experimental and clinical studies.
The outcome of this challenge was similar to the clinical output in IBD patients. By the simula-
tion of TNFα or MACR knockout (simulating Granulocyte and Monocyte Apheresis), a
decrease in MMPs node was observed, which is in line with therapy success in clinical practice
by a decrease in Crohn’s Disease Activity Index (CDAI) Score [42–46],[62–68]. On other
hand, IL17 or IFNγ knockout or IL10 overexpression did not show major change in MMPs
expression, suggested a failed therapy as was indeed found in clinical practice [69–72].
Surprisingly, the model shows that a knockout of IL2 leads to a reduction in MMPs similar
to that of a knockout of TNFα, even when previous results of clinical trials with Basiliximab or
Daclizumab (monoclonal antibodies that bind to the interleukin 2 receptor CD25) in Ulcera-
tive Colitis have failed to show superiority to corticosteroids alone [73,74]. The mechanism of
Fig 2. IBD network perturbation analysis and clustering. The heatmap indicates the effect of single blockage of each node (columns) in every network
node (rows). The colour in each cell corresponds to the Perturbation Index (PI) of the nodes. When there is no change in the expression of the node, the
cells of the heatmap would be black, having a value between 0.8 and 1.25 in their PIs. Otherwise, when the perturbation causes an overexpression in a
node, the cell in the heatmap would be orange coloured, with PIs values greater than 1.25. On the contrary, a value of 0.8 or smaller, blue colour, indicates
that the perturbation causes a downregulation of the node. The numeric scale in the legend represents different values of the nodes PI under different
perturbations. Nodes that induce similar alterations are hierarchically clustered.
https://doi.org/10.1371/journal.pone.0192949.g002
Table 3. Expression of network nodes in IBD patients.
NODE EXPRESSION NODE EXPRESSION NODE EXPRESSION NODE EXPRESSION
PGN
MDP
LPS
Altered IL1b Upregulated Th2 Upregulated DC Downregulated in Blood-Upregulated in
mucosa
TLR2 Upregulated IFNg Upregulated IL4 Altered IEC_MICA_B Upregulated
TLR4 Upregulated IL23 Upregulated IL15 Upregulated IEC_ULPB1_6 Upregulated
NOD2 Altered IL22 Upregulated IL12 Upregulated CD8_NKG2D Upregulated
NFkB Altered IL21 Upregulated IL13 Upregulated NK_NKG2D Unknown
IL6
TNFa
Upregulated
Upregulated
IL17 Upregulated Treg Downregulated in Blood-Upregulated in
mucosa
CD4_NKG2D Upregulated
TGFb Upregulated IL10 Upregulated NK Upregulated FIBROBLAST Upregulated
Th0 Unknown Th17 Upregulated DEF Altered MMPs Upregulated
Th0_M Upregulated Th17_M Upregulated IL2 Upregulated PERFOR Altered
IL18 Upregulated Th1 Altered MACR Unknown GRANZB Upregulated
A total of 31 nodes are reported as upregulated in IBD patients, 9 are reported to be altered (when different reports from literature are inconclusive or contradictory)
and 3 nodes are unknown.
https://doi.org/10.1371/journal.pone.0192949.t003
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action of corticosteroids has not been fully described, yet it is known that corticosteroids cause
diminished levels of IL2 mRNA [75,76]. Together with the rest of corticosteroid inhibitory
mechanisms, this would be the reason why Basiliximab or Daclizumab do not show superiority
to corticosteroids alone.
Among the potential applications the current network supports: (i) biomarker selection
given that the cytokines TNFα, IL21, IL17 and IL1ß, which can be easily measured in periph-
eral plasma with different Enzyme-linked immunosorbent assay (ELISA) kits [77,78], are the
model components directly related to MMPs activation, (ii) search for optimal combination
therapy to overcome the high attrition rates in phase clinical trials with single therapies which
Fig 3. IBD network simulation results. Attractor state of every network node for healthy and IBD simulated individuals under chronic antigen exposure.
https://doi.org/10.1371/journal.pone.0192949.g003
A systems pharmacology model for IBD
PLOS ONE | https://doi.org/10.1371/journal.pone.0192949 March 7, 2018 10 / 19
are due mainly to lack of efficacy [79], and (iii) management of multiscale information such as
the integration of proteomic gene expression data [55] accounting for IBD polymorphisms to
anticipate responders and non-responders. With such a type of data able to correlate a genetic
alteration with a decrease or an increase in protein expression, it would be possible to simulate
specific genetic alteration by altering the protein expression. This would allow one of the limi-
tations of the current network at the present time to be overcome with regard to the effects of
Ustekinumab, a monoclonal antibody targeting free IL12 and IL23, which has been recently
approved for moderately to severely active Crohn’s disease in adults who have failed to treat-
ment with immunomodulators, or more than one TNFα blocker [80]. Simulation results
based on the known mechanisms of Ustekinumab showed just a 4.1% decrease in tissue dam-
age. On the other hand, when simulating TNFα blocker effects, tissue damage decreased by
30.6% even though a substantial percentage of patients showed poor control of the disease
after treatment with anti-TNFα antibody [15,16].
We emphasize that the proposed network model is fully accessible which allows it to
undergo immediate testing and further development. In that respect it should be noted that
although our model intended to include information of human origin exclusively, some criti-
cal pathways had to be complemented with animal derived data (although in the current case
the percentage of human supported pathways is greater than in previous computational mod-
els [20,81,82]), but we are aware of the wide differences in the immune system between species
[83–85].
Fig 4. Comparison of MMPs expression after the simulation in IBD simulated individuals of different therapies.
Simulated therapies: Anti-TNFα, GMA therapy (equivalent of knock out our MACR node), anti-IL17, human
recombinant IL10 (rhulL-10), anti-IFNγ, anti-IL2 and anti-IL12-IL23. Comparing with untreated simulation, we can
see a 30.7%, a 27.1%, a 31.9% and a 4.1% decrease in the MMPs expression simulating anti-TNFα, GMA therapy, anti-
IL2 and anti-IL12-IL23 respectively. There is no major change in MMPs expression for the two which failed in clinical
trials anti-IL17 (a 6.5% decrease) and human recombinant IL10 (a 3.2% decrease). Otherwise, anti-IFNγ therapy
simulation shows an increase in MMPs expression of 16.0% compared to Untreated.
https://doi.org/10.1371/journal.pone.0192949.g004
A systems pharmacology model for IBD
PLOS ONE | https://doi.org/10.1371/journal.pone.0192949 March 7, 2018 11 / 19
This study addresses the goals of systems pharmacology by effectively encompassing prior
knowledge to generate a mechanistic and predictive understanding at the systems level for
IBD. Semi-quantitative understanding at the network level is necessary prior to the generation
of detailed quantitative models for within-host disease dynamics. The current IBD model and
the companion literature summary archive will drive the development of a dynamic (i.e., ordi-
nary differential equation driven) model involving meaningful parameters capable of simulat-
ing longitudinal data, and allowing model reduction as well the goal of parameter estimation
during the clinical stages of the drug development process. In addition, our IBD network can
be extended to other inflammatory diseases, as main pathways in the model are common to
most inflammatory conditions [86,87], and the outputs of our nodes could also serve as inputs
to broader-scale logic models; for example, incorporating structures from available logic mod-
els of some of our nodes such as fibroblast [61], IL1b or IL6 [88].
In summary, we present a network model for inflammatory bowel disease which is available
and ready to be used and can cope with (multi-scale) model extensions. It is supported by a
comprehensive repository summarizing the results of the most relevant literature in the field.
This model proved to be promising for the in silico evaluation of potential therapeutic targets,
the search for pathway specific biomarkers, the integration of polymorphisms for patient strat-
ification, and can be reduced and transformed in quantitative model/s.
Methods
Literature search and data selection
The network model is based on an exhaustive bibliographic review focusing on the essential
components of IBD, as previously performed by Ruiz-Cerda´ et al., in their systems pharmacol-
ogy approach for lupus erythematosus [23]. Our review included around 620 papers published
between October 1984 and September 2017, yet the most common reviewed articles were from
2007 or later (76%). The search of the relevant literature was made through Medical Subject
Headings (MeSH) terms using different search engines such as PubMed, clinicaltrials.gov or
google scholar. MeSH terms were focused on the combination of keywords and free words
including: (i) relevant network components (ej.”IL6”) involved in the pathogenesis of IBD, (ii)
nodes that have been reported to be altered in IBD (ej. “IL6 AND IBD”) and (iii) nodes directly
affecting the expression of the nodes selected in (i) and (ii) (ej. “DC AND IL6”). The internal
nodes selection was made according to the reported upregulated components in IBD patients
together with the nodes (immune system cells) which are necessary to link the upregulated
nodes, which were established as internal nodes. Only original papers with a clear description
of experimental conditions were considered to identify the relationships between the compo-
nents of the biological network. Due to the reported differences between animal and human
immunology [83–85], in only few cases were animal data considered to connect nodes of criti-
cal pathways when no human data were available.
Annotation and system representation
Annotation was crucial to organize the available literature according to its relevance. S2 Table
from supplementary information shows the way the information was organized for building
the network. S2 Table includes every node definition and the relationships between the nodes.
Annotation included the identification of the main elements (antigens, cytokines, cells, pro-
teins, membrane receptors and ligands) of IBD disease.
The IBD model will be freely accessible to the public through the “The Cell Collective”
repository https://cellcollective.org/#cb963d7f-75cb-4b2e-8987-0c7592a9c21d.
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Boolean network building and r implementation
The collection of qualitative relationships extracted from the literature was transformed into a
logical model as described before by Ruiz-Cerda´ et al. [23]. Logic networks capture the dynam-
ics of their components, called nodes, after selected stimuli or initial conditions [89,90]https://
paperpile.com/c/XvtklO/p0BRz+YiQ4q. In these models the relationships of activation or
inhibition between nodes are described as combinations of the logic operators: AND, OR and
NOT condensed in a mathematical expression called a Boolean function for each node. Posi-
tive and negative modulators, and thresholds as previously described by Ruiz-Cerda´ et al.[23]
and Irurzun-Arana et al. [28] were also considered to resemble better the biological system.
Boolean network building and R implementation from S1 File gives a more detailed explana-
tion of the modulators used in the model.
Simulations
The set of combined Boolean functions for the IBD model was implemented SPIDDOR [28],
using RStudio Version 0.99.442. Simulations with 25 repetitions over 5000 iterations were per-
formed. According to preliminary experiments, these simulation conditions were required to
achieve the steady state of the network called attractor [91–93]. An attractor can be a fixed-
point if it composed of one state, a simple cycle if consists of more than one state that oscillates
in a cycle or a complex attractor if a set of steady-states oscillate irregularly. In each simulation,
a node can show two possible values in each iteration: 0 (deactivated) or 1 (activated). The per-
centage of activation of the output node (MMPs) calculated at the attractor state was used as
the readout summary of the simulation exercises, as this group of proteins are directly associ-
ated with intestinal fibrosis and tissue damage in IBD [42–46].
Each node was updated asynchronously [94–96] according to its Boolean function that
defines the dynamics of the system. Initial conditions are explained in detail in “Simulations”
from S1 File.
Perturbation analysis and clustering
Robustness can be defined as the system’s ability to function normally under stochastic pertur-
bations [96]. The investigation of robustness in Boolean networks generally focuses on the
dependence between robustness and network connectivity [97]. We performed a perturbation
analysis in our IBD model to study robustness by simulating the effect of the single blockage of
each node on every other node of the network [51]. This simulation was performed by using
the KO_matrix.f function from SPIDDOR package with 24 repetitions over 999 iterations
under asynchronous updating.
Results from the simulations described above were represented as heatmaps with dendro-
grams in which the number of rows and columns is equal to the number of nodes in the net-
work (Fig 2). The colour in each cell of the heatmap corresponds to the Perturbation Index(PI)
of the nodes, which is the probability ratio between the perturbed and the normal conditions
as described by Irurzun-Arana et al. [28]. A hierarchical clustering method [98] was applied to
further study which nodes cause similar alterations in the system.
Network accuracy and validation
Accuracy was evaluated comparing the alterations reported in the literature for IBD patients
with the simulations of chronic antigen exposure for IBD or healthy individuals.
A literature search of every node expression in IBD patients was performed, and the gath-
ered information is condensed in S3 Table including three categories: up-, down-regulated, or
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altered, whether the levels in CD, UC or both (IBD) with respect to healthy volunteers are
higher, lower, or inconclusive and/or contradictory, respectively.
For validation purposes, model simulations were compared against available results from
clinical trials performed in IBD, CD or UC until the beginning of 2017 in https://www.
clinicaltrials.gov/. All the molecules tested in clinical trials, whose mechanism of action is
known and whose target were included in our network, were tested with the model. The net-
work was evaluated comparing simulations and reported outcomes from clinical trials for six
investigated molecules: anti-TNFα [62–65] and anti-IL12-IL23 [80], two monoclonal antibod-
ies (mAb) approved for IBD disease, anti-IFNγ [69,70], anti-IL17 [72], anti-IL2 [73,74] and
human recombinant IL10 (rhuIL-10) [71] which failed in clinical trials. Also a new promising
therapy: Granulocyte and Monocyte Apheresis (GMA) [66–68] was tested. The reported
CDAI (Crohn Disease Activity Index) was compared with the average expression of the MMPs
output node in the attractor state.
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